Regenxbio (RGNX) Total Non-Current Liabilities (2018 - 2026)
Regenxbio (RGNX) posted quarterly Total Non-Current Liabilities of $349.7 million for Q4 2025, up 72.5% year-over-year from $202.7 million in Q4 2024, and down 3.7% quarter-over-quarter from $363.1 million in Q3 2025.
Regenxbio (RGNX) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
Regenxbio's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $349.7 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 72.5% year-over-year to $349.7 million; the TTM figure through Dec 2025 stood at $349.7 million (up 72.5% YoY), while the FY2025 annual figure was $349.7 million, up 72.5% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $349.7 million, down from $363.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $366.7 million in Q2 2025, with the low at $178.1 million in Q2 2021.
- The 5-year median for Total Non-Current Liabilities is $249.8 million (2023), against an average of $258.1 million.
- The sharpest annual moves came in 2021 and 2024: Total Non-Current Liabilities jumped 652.67% in 2021, then plunged 30.95% in 2024.
- Regenxbio's Total Non-Current Liabilities stood at $178.3 million in 2021, then rose by 0.68% to $179.5 million in 2022, then grew by 21.88% to $218.7 million in 2023, then fell by 7.33% to $202.7 million in 2024, then jumped by 72.5% to $349.7 million in 2025.
- Business Quant data shows RGNX's Total Non-Current Liabilities at $349.7 million in Q4 2025, $363.1 million in Q3 2025, and $366.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 314.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 314.37 Mn |
| Dec 31, 2025 | 349.66 Mn |
| Sep 30, 2025 | 363.10 Mn |
| Jun 30, 2025 | 366.68 Mn |
| Mar 31, 2025 | 205.61 Mn |
| Dec 31, 2024 | 202.70 Mn |
| Sep 30, 2024 | 182.65 Mn |
| Jun 30, 2024 | 217.59 Mn |
| Mar 31, 2024 | 235.06 Mn |
| Dec 31, 2023 | 218.74 Mn |
| Sep 30, 2023 | 264.50 Mn |
| Jun 30, 2023 | 270.52 Mn |
| Mar 31, 2023 | 276.71 Mn |
| Dec 31, 2022 | 179.47 Mn |
| Sep 30, 2022 | 311.31 Mn |
| Jun 30, 2022 | 314.40 Mn |
| Mar 31, 2022 | 328.02 Mn |
| Dec 31, 2021 | 178.26 Mn |
| Sep 30, 2021 | 194.67 Mn |
| Jun 30, 2021 | 178.08 Mn |